GlassScriptPhysician profile
Khurram Anwar
NPI 1619211745
$928.47
in general payments reported to CMS, 2019-2025
15 companies · $43.25 in 2025
The $43.25 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.04 · 2020: $106 · 2022: $309 · 2023: $361 · 2024: $69.99 · 2025: $43.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.33 |
| Education | $113.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $178.25 | 2023-2025 | Calquence, Enhertu |
| Seagen INC. | $158.76 | 2022-2023 | |
| Genentech USA, INC. | $150.00 | 2022 | |
| Beigene USA, INC. | $85.55 | 2023 | Brukinsa |
| Eisai INC. | $82.78 | 2023 | |
| Incyte Corporation | $69.99 | 2024 | |
| Pfizer INC. | $41.31 | 2020-2023 | |
| Boston Scientific Corporation | $36.84 | 2020 | |
| Novartis Pharmaceuticals Corporation | $27.85 | 2023 | |
| Merck Sharp & Dohme LLC | $25.49 | 2019 | |
| Sobi, INC | $15.61 | 2022 | |
| Amgen INC. | $14.45 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.40 | 2020 | |
| Ucb, INC. | $13.64 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khurram Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.